Priority from the Idiopathic Intracranial Hypertension PSP
| UNCERTAINTY: Do the benefits of the drug treatments for IIH outweigh the side effects? | |
|---|---|
| Overall ranking | This was one of the 16 questions at the workshop that fell outside of the Top 10. |
| JLA question ID | 0066/14 |
| Explanatory note | Not available for this PSP |
| Evidence |
None identified |
| Health Research Classification System category | Neurological |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Should all individuals be counselled regarding weight loss despite their starting BMI? ~ What is the safety (in terms of medication overuse outcomes), efficacy and optimum dose of acetozolamide for chronic treatment of raised intracranial pressure in people with IIH? ~ What is the maximum therapeutic dose of acetazolemide that should be given to treat vision problems in people with IIH? |
| Submitted by | See data spreadsheet on JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0066 |
| PSP name | Idiopathic Intracranial Hypertension |
| Total number of uncertainties identified by this PSP. | 48 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 27 April 2018 |